Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZBIO Zenas BioPharma Inc.

盘前交易 04-27 07:01:08 EDT

18.19

-0.30

-1.62%

最高18.64	最低17.63	成交量56.47万
今开18.40	昨收18.49	日振幅5.44%
总市值11.35亿	流通市值7.25亿	总股本6,237万
成交额1,026万	换手率1.42%	流通股本3,984万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":18.19,"timestamp":1777060800000,"preClose":18.49,"halted":0,"volume":564707,"delay":0,"changeRate":-0.01622498647917778,"floatShares":39841600,"shares":62371044,"eps":-8.44,"marketStatus":"盘前交易","change":-0.3,"latestTime":"04-27 07:01:08 EDT","open":18.4,"high":18.635,"low":17.63,"amount":10260995.555239001,"amplitude":0.054354,"askPrice":18.19,"askSize":13,"bidPrice":16.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-8.44,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777296600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":18.19,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":18.19,"preClose":18.19,"latestTime":"17:43 EDT","volume":8818,"amount":160387.14,"timestamp":1777067028495,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3554006214398375,"impliedVol":1.0215,"impliedVolPercentile":0.6545},"requestUrl":"/m/hq/s/ZBIO","defaultTab":"news","newsList":[{"id":"1123848176","title":"Zenas BioPharma完成3亿美元融资：发行可转债与普通股，加速自免药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1123848176","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123848176?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:13","pubTimestamp":1774584809,"startTime":"0","endTime":"0","summary":"Zenas BioPharma完成3亿美元融资：发行可转债与普通股，加速自免药物开发生物制药公司Zenas BioPharma宣布，已完成同时公开发行2032年到期的2.50%可转换优先票据和普通股，募集资金总额达3亿美元。公司计划将净收益主要用于推进obexelimab的全球三期临床试验，以及其他早期自免候选药物的研究。自免疾病赛道竞争加剧Zenas BioPharma专注于开发针对自身免疫性疾病的创新疗法。此次融资将为Zenas提供充足的资金跑道，支持其关键临床试验的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133548955","title":"Zenas BioPharma Inc. 融资收益将用于支持Obexelimab美国上市、管线推进及一般企业用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1133548955","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133548955?lang=zh_cn&edition=full","pubTime":"2026-03-27 04:03","pubTimestamp":1774555391,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. 近日宣布，其通过融资所获收益将专项用于支持其核心产品Obexelimab在美国市场的商业化上市准备工作。此外，部分资金也将用于推动公司研发管线的进一步拓展，以及其他一般企业运营目的。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148820224","title":"Zenas BioPharma宣布拟同步公开发行2032年到期可转换优先票据及普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1148820224","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148820224?lang=zh_cn&edition=full","pubTime":"2026-03-27 04:02","pubTimestamp":1774555361,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.披露了同步进行两项公开募资的计划：发行2032年到期的可转换优先票据，以及公司普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126645156","title":"Zenas BioPharma 公布2025年第四季度及全年财务业绩并更新公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1126645156","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126645156?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:01","pubTimestamp":1773658872,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) 已正式发布其2025年第四季度及全年的财务报告。此次公告同时包含了公司最新的运营动态与发展规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609651785","title":"Zenas Biopharma, Inc.盘中异动 股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609651785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609651785?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:41","pubTimestamp":1770388865,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日22时41分，Zenas Biopharma, Inc.股票出现异动，股价急速上涨5.14%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Klotho Neurosciences Inc C/Wts 21/06/2029 、Liminatus Pharma Inc C/Wts 30/04/2030 涨幅较大，Clearmind Medicine Inc.、Liminatus Pharma, Inc.、Aim Immunotech Inc.较为活跃，换手率分别为418.51%、18.28%、15.33%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Cingulate Inc C/Wts 10/12/2026 、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为47.83%、21.54%、18.03%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206224106a6dc117c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206224106a6dc117c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608539373","title":"Zenas Biopharma, Inc.盘中异动 股价大涨5.12%报19.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608539373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608539373?lang=zh_cn&edition=full","pubTime":"2026-02-03 23:05","pubTimestamp":1770131141,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日23时05分，Zenas Biopharma, Inc.股票出现异动，股价大幅上涨5.12%。截至发稿，该股报19.08美元/股，成交量8.8393万股，换手率0.16%，振幅5.45%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.86%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020323054197a4b3ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020323054197a4b3ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605455713","title":"Zenas Biopharma, Inc.盘中异动 早盘急速下挫5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605455713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605455713?lang=zh_cn&edition=full","pubTime":"2026-01-22 00:21","pubTimestamp":1769012470,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日00时21分，Zenas Biopharma, Inc.股票出现波动，股价快速跳水5.12%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。其相关个股中，Lisata Therapeutics, Inc.、Moolec Science Sa、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Aditxt, Inc.、Revelation Biosciences, Inc.、Lisata Therapeutics, Inc.较为活跃，换手率分别为1204.36%、81.52%、46.59%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Jasper Therapeutics Inc C/Wts 24/09/2026 、Io Biotech, Inc.，振幅分别为71.60%、68.10%、45.77%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122002110a4465546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122002110a4465546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195864515","title":"Zenas BioPharma股价因免疫疾病药物后期数据不佳而跌至逾四个月低点，日内跌幅达55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195864515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195864515?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:30","pubTimestamp":1767627041,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) 股价近日遭遇重挫，创下逾四个月以来的新低。此次股价大幅下跌的主要原因是其免疫疾病药物的后期临床试验数据未达市场预期，导致投资者信心受挫。截至最新交易时段，该公司股价当日跌幅高达55%，反映出市场对其药物研发前景的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165846039","title":"Zenas BioPharma公布Obexelimab治疗IgG4相关疾病3期INDIGO注册试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1165846039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165846039?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:06","pubTimestamp":1767614762,"startTime":"0","endTime":"0","summary":"Zenas BioPharma宣布，其药物Obexelimab在针对免疫球蛋白G4相关疾病（IgG4-RD）的3期INDIGO注册试验中取得了积极成果。该试验达到了主要终点，显示出显著疗效和良好安全性，为后续监管申报奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133394639","title":"InnoCare Pharma宣布Orelabrutinib（Btk抑制剂）在系统性红斑狼疮的2B期研究中实现主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1133394639","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133394639?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:07","pubTimestamp":1765800457,"startTime":"0","endTime":"0","summary":"InnoCare Pharma宣布在针对系统性红斑狼疮的Orelabrutinib（Btk抑制剂）2B期研究中实现了主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142056905","title":"Zenas BioPharma：Obexelimab三期Indigo试验在免疫球蛋白G4相关疾病（IgG4-RD）中的初步结果预计将在年末公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1142056905","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142056905?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:13","pubTimestamp":1762949593,"startTime":"0","endTime":"0","summary":"Zenas BioPharma：Obexelimab三期Indigo试验在免疫球蛋白G4相关疾病（IgG4-RD）中的初步结果预计将在年末公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122038621","title":"Zenas Biopharma公布Obexelimab在复发性多发性硬化症II期Moonstone试验中取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1122038621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122038621?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:08","pubTimestamp":1761563296,"startTime":"0","endTime":"0","summary":"Zenas Biopharma公布Obexelimab在复发性多发性硬化症II期Moonstone试验中取得积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165438252","title":"Zenas Biopharma预计将在2026年第一季度启动Orelabrutinib针对继发渐进性多发性硬化症患者的全球三级临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165438252","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165438252?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:08","pubTimestamp":1761563293,"startTime":"0","endTime":"0","summary":"Zenas Biopharma预计将在2026年第一季度启动Orelabrutinib针对继发渐进性多发性硬化症患者的全球三级临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136169257","title":"异动解读 | 生物科技新星Zenas BioPharma首秀大涨11.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136169257","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136169257?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:00","pubTimestamp":1726246829,"startTime":"0","endTime":"0","summary":"今日,生物科技公司Zenas BioPharma Inc. 在纳斯达克成功完成IPO,股价大涨11.71%,引发市场关注。当日Zenas IPO发行价为17美元,开盘股价则为18.35美元,较发行价溢价8%。Zenas在本次IPO中发行1320万股,募集资金2.25亿美元,超过了原计划规模。随着美国IPO新股市场近期回温,投资者对Zenas这样前景可期的生物科技股青睐有加,均有望成为推动其当日首秀股价大涨的重要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":-0.1664},{"period":"1month","weight":-0.1803},{"period":"3month","weight":-0.0946},{"period":"6month","weight":-0.2388},{"period":"1year","weight":0.8226},{"period":"ytd","weight":-0.499}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zenas BioPharma, Inc.最初于2019年11月12日在开曼注册成立，名称为Zenas BioPharma（Cayman）Limited。2023年8月2日，该公司在特拉华州成立，同时将其名称从Zenas BioPharma（Cayman）Limited更改为Zenas BioPharma, Inc.。该公司是一家临床阶段的全球生物制药公司，致力于为有需要的患者开发和商业化基于免疫的变革疗法。随着对自身免疫性疾病发病机制的不断了解，以及有前景的基于免疫学的药理学靶点的扩展，他们正在建立一家专注于免疫学和炎症（“I&I”）的生物制药公司。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Zenas BioPharma Inc.(ZBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Zenas BioPharma Inc.(ZBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}